Investment Thesis
Whitehawk Therapeutics exhibits fundamental deterioration with zero revenue, -$23.5M operating losses, and -$22.2M quarterly cash burn with limited runway (~2 quarters) from $34.8M cash reserves. Despite a strong balance sheet and minimal debt, the company faces existential execution risk as a pre-revenue pharmaceutical with no commercial traction and mounting losses.
Strengths
- Strong balance sheet with $34.8M cash and $116.2M stockholders equity
- Zero debt with 0.00 Debt/Equity ratio and high liquidity ratios (11.36x current ratio)
- Low liabilities at $11.1M relative to total assets of $127.2M
Risks
- Zero revenue (-72.5% YoY) indicating failed or absent commercialization
- Unsustainable cash burn of -$22.2M per period with approximately 1.5-2 quarters of runway remaining
- Significant insider activity (14 Form 4 filings in 90 days) suggesting potential concerns from company insiders
- Negative profitability with -$23.5M operating income and -17.4% ROA
- Pre-revenue biotech model carries extreme execution risk with no proven commercial success
Key Metrics to Watch
- Quarterly cash burn rate and total cash runway estimates
- Revenue generation timeline and commercialization milestones
- R&D pipeline progress and clinical trial developments
Financial Metrics
Revenue
0.0
Net Income
-22.2M
EPS (Diluted)
$-0.32
Free Cash Flow
-22.2M
Total Assets
127.2M
Cash
34.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-19.1%
ROA
-17.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
11.36x
Quick Ratio
11.36x
Debt/Equity
0.00x
Debt/Assets
8.7%
Interest Coverage
-405.55x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:42:13.785452 |
Data as of: 2026-03-31 |
Powered by Claude AI